Jay Hancock, Senior Correspondent, joined KHN in 2012 from The Baltimore Sun, where he wrote a column on business and finance. Previously he covered the State Department and the economics beat for The Sun and health care for The Virginian-Pilot of Norfolk and the Daily Press of Newport News. He has a bachelor’s degree from Colgate University and a master’s in journalism from Northwestern University.
Jay Hancock
From this contributor
By
Jay Hancock, Sydney Lupkin, Elizabeth Lucas, Kaiser Health News
21 April 2017
5 min read
Health companies gave generously to President Trump’s inauguration
Facing acute risks to their businesses from Washington policymakers, health companies spent more than $2 million to buy access to the incoming Trump administration via candlelight dinners, black-tie balls and other inauguration events.
Health companies gave generously to President Trump’s inauguration
By
Jay Hancock, Sydney Lupkin, Elizabeth Lucas, Kaiser Health News
21 April 2017 | 5 min read
Explore more from The Transmitter
Cell population in brainstem coordinates cough, new study shows
The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.
Cell population in brainstem coordinates cough, new study shows
The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.
By
Calli McMurray
6 September 2024 | 5 min read
In updated U.S. autism bill, Congress calls for funding boost, expanded scope
The current Autism CARES Act sunsets in late September.
In updated U.S. autism bill, Congress calls for funding boost, expanded scope
The current Autism CARES Act sunsets in late September.
By
Rachel Zamzow
5 September 2024 | 5 min listen
Ketamine targets lateral habenula, setting off cascade of antidepressant effects
The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.
Ketamine targets lateral habenula, setting off cascade of antidepressant effects
The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.
By
Olivia Gieger
4 September 2024 | 6 min read